Detalhe da pesquisa
1.
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Br J Cancer
; 128(2): 245-254, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36352028
2.
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
J Vasc Interv Radiol
; 33(9): 1034-1044.e29, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526675
3.
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
BMC Cancer
; 12: 436, 2012 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23020514
4.
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies.
JMIR Res Protoc
; 8(10): e13696, 2019 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31579027
5.
A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer.
Sci Rep
; 5: 11385, 2015 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26077929